| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VTFN from our risk checks.
Vitrolife AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr13.74 |
| 52 Week High | kr21.04 |
| 52 Week Low | kr10.66 |
| Beta | 1.58 |
| 1 Month Change | -19.08% |
| 3 Month Change | -9.31% |
| 1 Year Change | -30.95% |
| 3 Year Change | -55.99% |
| 5 Year Change | -25.16% |
| Change since IPO | 2,542.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| VTFN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.8% | -1.2% | 1.7% |
| 1Y | -31.0% | -23.0% | 2.3% |
Return vs Industry: VTFN underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: VTFN underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| VTFN volatility | |
|---|---|
| VTFN Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VTFN's share price has been volatile over the past 3 months.
Volatility Over Time: VTFN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,132 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB (publ) provides assisted reproduction products. It also offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. In addition, the company offers EmbryoScope and time-lapse systems; time-lapse dishes; and evaluation tools for time-lapse systems.
Vitrolife AB (publ) Fundamentals Summary
| VTFN fundamental statistics | |
|---|---|
| Market cap | €1.89b |
| Earnings (TTM) | -€329.54m |
| Revenue (TTM) | €300.59m |
6.3x
P/S Ratio-5.7x
P/E RatioIs VTFN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTFN income statement (TTM) | |
|---|---|
| Revenue | kr3.50b |
| Cost of Revenue | kr1.53b |
| Gross Profit | kr1.97b |
| Other Expenses | kr5.81b |
| Earnings | -kr3.84b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 17, 2024
| Earnings per share (EPS) | -28.33 |
| Gross Margin | 56.39% |
| Net Profit Margin | -109.63% |
| Debt/Equity Ratio | 14.9% |
How did VTFN perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield-4%
Payout RatioDoes VTFN pay a reliable dividends?
See VTFN dividend history and benchmarks| Vitrolife dividend dates | |
|---|---|
| Ex Dividend Date | Apr 26 2024 |
| Dividend Pay Date | May 03 2024 |
| Days until Ex dividend | 0 days |
| Days until Dividend pay date | 7 days |
Does VTFN pay a reliable dividends?
See VTFN dividend history and benchmarks